U.S. regulators approved two novel antibiotics for gonorrhea: Innoviva’s zoliflodacin (Nuzolvence) and GSK’s gepotidacin (Blujepa). Both agents received priority review and qualified infectious disease product designations and add new oral options against a pathogen with rising resistance to current regimens. The approvals expand treatment choices and will affect stewardship strategies and susceptibility testing guidelines as clinics adopt the new agents.